Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-04-26 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
2025年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2025年度财务决算报告 (2025 Annual Financial Settlement Report) of 恩威医药股份有限公司, which includes audited financial statements for the year ended December 31, 2025. It contains detailed financial data such as revenue, net profit, cash flows, assets, liabilities, and financial ratios. The audit report number and auditor's opinion are included, indicating it is a full annual financial report. The length is 3403 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, this document is best classified as an Annual Report (10-K equivalent).
2026-04-26 Chinese
独立董事2025年度述职报告（彭刚）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for Enwei Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance at board and committee meetings, oversight activities, and evaluations related to the company's governance, financial reporting, internal controls, and shareholder interests for the year 2025. The content focuses on the director's role and activities rather than presenting financial statements or audit results. It is not an audit report, annual report, or earnings release. It is a management-related report focusing on board and governance activities, specifically the independent director's annual work report. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length (4808 characters) and detailed content support this classification with high confidence.
2026-04-26 Chinese
中信证券股份有限公司关于恩威医药股份有限公司2025年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an opinion from CITIC Securities Co., Ltd. regarding the internal control self-evaluation report of Enwei Pharmaceutical Co., Ltd. for the year 2025. It discusses the internal control evaluation, standards for defects in financial and non-financial reporting, and the conclusion that no major defects were found. It also references an internal control audit report issued by an accounting firm. The document is a verification or audit opinion on the internal control self-evaluation report rather than the report itself. It does not contain full financial statements or detailed financial data but rather an assessment and opinion on the internal control report. The document length is under 5,000 characters and appears to be a standalone audit or verification opinion related to internal controls. Therefore, it fits best under Audit Report / Information (AR).
2026-04-26 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, management, adjustment, and recovery mechanisms of remuneration for directors and senior management of the company. It references relevant laws and governance codes, and outlines the remuneration policy and procedures. There is no financial data, no report of financial results, no voting results, no announcement of a report, no legal proceedings, no capital changes, no earnings release, no call transcript, and no merger or acquisition activity. The content is clearly about executive compensation policies and governance. Therefore, the document fits the category of Remuneration Information (DEF 14A). The document length is 2754 characters, which is consistent with a detailed policy document rather than a brief announcement or report publication notice. Confidence is high due to the clear focus on remuneration policy and absence of other report types.
2026-04-26 Chinese
关于2025年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and usage of raised funds for the year 2025 by 恩威医药股份有限公司. It details the amount of funds raised, their allocation, usage during the year, interest income, cash management products, and compliance with regulatory requirements. The document references regulatory rules related to fundraising and fund management, and includes detailed financial figures about the raised funds and their usage. This type of report is a specialized disclosure on the use of capital raised from a public offering, which fits the category of Capital/Financing Update (CAP). It is not a full annual or interim financial report, nor an announcement of a report publication. The document length and content confirm it is a substantive report on fundraising capital usage.
2026-04-26 Chinese
关于召开2025年年度股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Enwei Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and logistical details for the AGM. The document length is 4111 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.